Consistent with our findings, Met can repress GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib [15], and inhibit 2DG-induced autophagy to sensitize 2DG in prostate cancer cells [32]. The gene discussed is HSPA5; the disease is prostate carcinoma.